Effect of clofibric acid on desmin and vimentin contents in rat myocardiocytes

被引：1

作者：

Sampayo-Reyes, Adriana

Narro-Juarez, Antonio

Said-Fernandez, Salvador

Lozano-Garza, Hector G.

Vargas-Villareal, Javier

Mata-Cardenas, Benito D.

Morales-Aquilera, Antonio

Gonzalez-Garza, Maria Teresa

Cortes-Gutierrez, Elva I.

Cerda-Flores, Ricardo M.

机构：

[1] Ctr Invest Biomed Noreste, Div Farmacol & Toxicol, Inst Mexicano Seguro Social, Mexico City 2, DF, Mexico

[2] Inst Mexicano Seguro Social, Div Biol Celular & Mol, Ctr Invest Biomed Noreste, Mexico City, DF, Mexico

[3] Escuela Med Inst Tecnol & Estudios Super Monterre, Mexico City, DF, Mexico

[4] Inst Mexicano Seguro, Div Genet, Mexico City, DF, Mexico

[5] Inst Mexicano Seguro, Ctr Invest Biomed Noreste, Mexico City, DF, Mexico

[6] Univ Auton Nuevo Leon, Fac Med, Unidad Labs Ingn & Expres Genet, Dept Bioquim, Mexico City, DF, Mexico

来源：

INTERNATIONAL JOURNAL OF TOXICOLOGY | 2006年 / 25卷 / 05期

关键词：

clofibrate; clofibric acid; desmin; myocardiocytes; vimentin;

D O I：

10.1080/10915810600846989

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The aim of this experimental study was to analyze in vitro effects of clofibric acid on vimentin and desmin contents in rat myocardiocytes, which was carried out in primary myocardiocyte cells that were treated only with clofibric acid at 0.1 mM. The measurement of vimentin and desmin were done by Western blotting and densitometry. This study showed that myocardiocytes exposed to clofibric acid exhibit a 26.3% decrease in vimentin and a 42.1% decrease in desmin. Considering the role that these intermediate filaments play in the anchorage and cellular organization of myocardiocytes, the decrease of desmin and vimentin observed in cells treated with clofibric acid may be partially responsible for the adverse effects observed in patients. In conclusion, the alteration of cytoskeletal proteins may be a cause of cardiopathy in patients treated with these compounds.

引用

页码：403 / 408

页数：6

共 22 条

[1] Hearts from mice lacking desmin have a myopathy with impaired active force generation and unaltered wall compliance [J].

Balogh, J ;

Merisckay, M ;

Li, Z ;

Paulin, D ;

Arner, A .

CARDIOVASCULAR RESEARCH, 2002, 53 (02) :439-450

[2]

BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3

[3]

BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5

[4] Desmin cytoskeleton: A potential regulator of muscle mitochondrial behavior and function [J].

Capetanaki, Y .

TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (08) :339-348

[5]

DAMATI G, 1992, MODERN PATHOL, V5, P165

[6] Mode of action and adverse effects of lipid lowering drugs [J].

Eghdamian, B ;

Ghose, K .

DRUGS OF TODAY, 1998, 34 (11) :943-956

[7] INFLUENCE OF FIBRIC ACID-DERIVATIVES ON INTERMEDIATE FILAMENT PROTEINS IN MYOCARDIOCYTE CULTURES [J].

GONZALEZ, FJ ;

ARANEGA, AE ;

LINARES, A ;

FERNANDEZ, JE ;

MUROS, MA ;

VELEZ, C ;

ALVAREZ, L ;

ARANEGA, A .

LIFE SCIENCES, 1991, 48 (11) :1091-1099

[8] Structural and functional analysis of a new desmin variant causing desmin-related myopathy [J].

Goudeau, B ;

Dagvadorj, A ;

Rodrigues-Lima, F ;

Nédellec, P ;

Casteras-Simon, M ;

Perret, E ;

Langlois, S ;

Goldfarb, L ;

Vicart, P .

HUMAN MUTATION, 2001, 18 (05) :388-396

[9] CHOLESTEROL REDUCTION YIELDS CLINICAL BENEFIT - A NEW LOOK AT OLD DATA [J].

GOULD, AL ;

ROSSOUW, JE ;

SANTANELLO, NC ;

HEYSE, JF ;

FURBERG, CD .

CIRCULATION, 1995, 91 (08) :2274-2282

[10]

IARC (International Agency for Reserch on Cancer), 1972, IARC MON EV CARC RIS

← 1 2 3 →